Our Experts

Andrew Rouff

Senior Consultant, Advisory Services

Expertise: Payer Market Research, Policy and Regulation, Industry Trends, Contracting, Reimbursement and Rebates, Biosimilars

Andrew Rouff is a senior consultant on the Advisory Services team at MMIT. A scientist by training, Andrew uses market research and analytics to help clients understand the unique opportunities and challenges in providing access for their brands. He earned a bachelor’s degree in Biochemistry from Union College and a master’s in Bioengineering from the University of Pennsylvania.

⟨ Back to Our Experts

Insights by Andrew Rouff

Article | June 12, 2025

Push for Change in 340B Drug Pricing Program

As the 340B Drug Pricing Program continues to grow in size and importance, its operations are being scrutinized more than ever. Pharma manufacturers, who have long noted issues with this program, have made various attempts at reform.

Article | April 24, 2025

What to Watch in Second Round of Medicare Drug Price Negotiations

Established by the Inflation Reduction Act in August 2022, the Medicare Drug Price Negotiation Program is still in its infancy, but is expected to impact a wide swath of stakeholders in the U.S. healthcare system.

Article | April 10, 2025

How Copay Accumulators and Maximizers Affect Pharma PAPs

In a recent post on specialty carve-out mechanisms, we examined how payers’ use of specialty benefit managers and alternative funding programs can impact manufacturers’ patient assistance programs (PAPs). Today’s post takes a look at another managed care trend: the rise of copay accumulators and maximizers, also known as copay adjustment programs.

Article | January 9, 2025

Meet Your Launch Goals with Payer and HCP Insights

The weeks preceding a pharma product’s launch date are a critical window for market access teams. The ability to pivot and adjust to last-minute shifts can make all the difference between a successful first year and a disappointing launch trajectory.

Article | January 2, 2025

What’s Ahead for Market Access in 2025?

As the pharma industry continues to adjust to the provisions of the Inflation Reduction Act (IRA), the country will soon be ushering in a new presidential administration—leaving the future of the IRA in question.

On-Demand Webinar | November 19, 2024

Payer and HCP Insights at Launch

In the immediate post-launch timeframe, pharma companies can use market access research to improve coverage and utilization. In this webinar, our experts explain the benefits of everything from post-label indication research to competitor analyses and payer/IDN perception tracking.

Article | October 17, 2024

How Costs Impact Utilization for Hemophilia CGTs

When the FDA approved the first cell and gene therapy (CGT) for hemophilia almost two years ago, it represented a massive leap forward in treating the bleeding disorder. The one-and-done agents offer the promise of a cure, giving patients the prospect of freedom from the disease without regular treatments.

Article | March 7, 2024

Treating Hemophilia: The Impact of New Gene Therapies

The CDC estimates that more than 33,000 Americans are living with hemophilia, an inherited bleeding disorder which affects primarily men. Patients with hemophilia have a deficiency of the blood proteins, known as coagulation or clotting factors, that help blood to clot properly.

Real-World Data Solutions

Payer Data Intelligence Solutions

Payer and Provider Insights Solutions

Payer and Specialty Pharmacy Solutions

Promotional Solutions

Market Access

Patient Journey

Brand Performance and Strategy

Contracting and Reimbursement